116 related articles for article (PubMed ID: 7664292)
21. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
22. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
23. 31P-nuclear magnetic resonance spectroscopy studies of the response of rat mammary tumors to endocrine therapy.
Rodrigues LM; Midwood CJ; Coombes RC; Stevens AN; Stubbs M; Griffiths JR
Cancer Res; 1988 Jan; 48(1):89-93. PubMed ID: 3335001
[TBL] [Abstract][Full Text] [Related]
24. Differential response of an ovarian-responsive mouse mammary tumor to androgenic and estrogenic agents.
Matsuzawa A; Ikeda Y
Cancer Res; 1983 Aug; 43(8):3680-6. PubMed ID: 6861137
[TBL] [Abstract][Full Text] [Related]
25. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
Mandlekar S; Yu R; Tan TH; Kong AN
Cancer Res; 2000 Nov; 60(21):5995-6000. PubMed ID: 11085519
[TBL] [Abstract][Full Text] [Related]
26. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.
Ye JJ; Liang SJ; Guo N; Li SL; Wu AM; Giannini S; Sachdev D; Yee D; Brünner N; Ikle D; Fujita-Yamaguchi Y
Horm Metab Res; 2003; 35(11-12):836-42. PubMed ID: 14710366
[TBL] [Abstract][Full Text] [Related]
27. Effects of tamoxifen and somatostatin analogue on growth of human medullary, follicular, and papillary thyroid carcinoma cell lines: tissue culture and nude mouse xenograft studies.
Weber CJ; Marvin M; Krekun S; Koschitzky T; Karp F; Benson M; Feind CR
Surgery; 1990 Dec; 108(6):1065-71. PubMed ID: 1978945
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
McDougal A; Wormke M; Calvin J; Safe S
Cancer Res; 2001 May; 61(10):3902-7. PubMed ID: 11358803
[TBL] [Abstract][Full Text] [Related]
29. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.
Gottardis MM; Wagner RJ; Borden EC; Jordan VC
Cancer Res; 1989 Sep; 49(17):4765-9. PubMed ID: 2758410
[TBL] [Abstract][Full Text] [Related]
30. A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice.
Simian M; Manzur T; Rodriguez V; de Kier Joffé EB; Klein S
Breast Cancer Res Treat; 2009 Jan; 113(1):1-8. PubMed ID: 18183485
[TBL] [Abstract][Full Text] [Related]
31. [Experimental combined chemo- and endocrine therapy with UFT and tamoxifen in human breast carcinoma xenografts serially transplanted into nude mice].
Kubota T; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2767-73. PubMed ID: 2074386
[TBL] [Abstract][Full Text] [Related]
32. Effects of estradiol and tamoxifen on creatine kinase in rodent mammary carcinomas.
Roghmann MC; Skinner KA; Hilf R
Cancer Res; 1987 Mar; 47(5):1348-53. PubMed ID: 3102045
[TBL] [Abstract][Full Text] [Related]
33. Changes in 31P nuclear magnetic resonance with tumor growth in radioresistant and radiosensitive tumors.
Koutcher JA; Alfieri AA; Barnett DC; Cowburn DC; Kornblith AB; Kim JH
Radiat Res; 1990 Mar; 121(3):312-9. PubMed ID: 2315448
[TBL] [Abstract][Full Text] [Related]
34. Experimental endocrinotherapy with tamoxifen of human ovarian dysgerminoma transplanted into nude mice.
Isonishi S
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Dec; 39(12):2185-92. PubMed ID: 3429992
[TBL] [Abstract][Full Text] [Related]
35. Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice.
Koibuchi Y; Iino Y; Uchida T; Andoh T; Horii Y; Nagasawa M; Horiguchi J; Maemura M; Takei H; Yokoe T; Morishita Y
Oncol Rep; 2000; 7(1):135-40. PubMed ID: 10601607
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol.
Jacobson HI; Bennett JA; Mizejewski GJ
Cancer Res; 1990 Jan; 50(2):415-20. PubMed ID: 1688512
[TBL] [Abstract][Full Text] [Related]
37. Dichotomous effects of tamoxifen on a transplantable rat mammary tumor.
Ip MM; Milholland RJ; Rosen F; Kim U
Cancer Res; 1981 Mar; 41(3):984-8. PubMed ID: 7459886
[TBL] [Abstract][Full Text] [Related]
38. Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model.
Zaino RJ; Satyaswaroop PG; Mortel R
Cancer Res; 1985 Feb; 45(2):539-41. PubMed ID: 3967228
[TBL] [Abstract][Full Text] [Related]
39. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.
Conley BA; Ramsland TS; Sentz DL; Wu S; Rosen DM; Wollman M; Eiseman JL
Cancer Chemother Pharmacol; 1999; 43(3):183-97. PubMed ID: 9923548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]